Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase NA 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 230Squamous Cell Carcinoma of Head and Neck 139Head and Neck Neoplasms 131Lung Neoplasms 117Esophageal Neoplasms 88Stomach Neoplasms 84Uterine Cervical Neoplasms 68Esophageal Squamous Cell Carcinoma 66Urinary Bladder Neoplasms 59Breast Neoplasms 55Nasopharyngeal Carcinoma 51Small Cell Lung Carcinoma 46Carcinoma, Squamous Cell 39Neoplasm Metastasis 38Pancreatic Neoplasms 36Neoplasms 35Biliary Tract Neoplasms 34Oropharyngeal Neoplasms 32Cholangiocarcinoma 32Ovarian Neoplasms 30Mesothelioma, Malignant 28Adenocarcinoma Of Esophagus 28Lymphoma 25Carcinoma 24Adenocarcinoma of Lung 24Central Nervous System Neoplasms 22Laryngeal Neoplasms 20Carcinoma, Ovarian Epithelial 20Recurrence 19Lymphoma, Large B-Cell, Diffuse 19

Interventions

Pemetrexed 2Bevacizumab 2tusamitamab ravtansine 1pembrolizumab 1ixabepilone 1Platinum 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Non-squamous Non-small Cell Lung Cancer × Cisplatin × Clear all
NCT06868836 2026-05-18

Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy

Shanghai Junshi Bioscience Co., Ltd.

Phase 2 Recruiting
78 enrolled
Thoracic

Non-squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡